{
  "abstract": "Introduction\n\nThe interleukin (IL)-4/IL-13 signaling pathway is central to the pathogenesis of atopic dermatitis (AD). Stapokibart (CM310) is a novel humanized monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα) subunit.Objective\n\nTo summarize current evidence on the mechanism of action, clinical efficacy, safety, and therapeutic potential of stapokibart for moderate-to-severe AD.Methods\n\nA narrative review was conducted based on a targeted search of PubMed/MEDLINE and ClinicalTrials.gov covering literature published from January 2015 to January 2026.Results\n\nStapokibart binds IL-4Rα with high affinity (KD = 0.25 nM), inhibiting downstream IL-4 and IL-13 signaling. In a phase 3 trial (N=500), stapokibart 300 mg every two weeks demonstrated significant improvements at Week 16, with 66.9% achieving EASI-75 (vs. 25.8% placebo) and 44.2% achieving IGA 0/1 (vs. 16.1% placebo; P<0.0001). Among responders, 92.5% maintained EASI-75 through Week 52. The treatment was generally well tolerated, with upper respiratory tract infections and injection-site reactions being the most common adverse events. Conjunctivitis occurred at low rates (5.0-5.9%).Conclusions\n\nStapokibart shows robust efficacy and a favorable safety profile in adults with moderate-to-severe AD, including sustained long-term responses and low conjunctivitis rates. While early data are encouraging, all comparisons with existing IL-4/IL-13 inhibitors are indirect, and further global phase 3 studies and real-world evidence are needed to define its role within treatment algorithms.",
  "abstract_shown": true,
  "affiliations": [
    "Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.",
    "The First School of Clinical Medicine, Southern Medical University, Guangzhou, China."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Esmeraldito Ferreira"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Tong Wu"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yongfeng Chen"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5bxp0avn7eyfa.bib",
  "cited_by": 0,
  "doi": "10.5826/dpc.1603a7230",
  "fulltext_url": "https://europepmc.org/articles/PMC13557268",
  "id": "5bxp0avn7eyfa",
  "issns": [
    "2160-9381"
  ],
  "landing_url": "https://europepmc.org/article/MED/42858405",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2708|Dermatology and Skin Diseases"
    ]
  ],
  "openalex": "W7172001587",
  "pdf_url": "https://europepmc.org/articles/PMC13557268?pdf=render",
  "pmcid": "PMC13557268",
  "pmid": "42858405",
  "published": "2026-07-31",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/5bxp0avn7eyfa.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:18Z",
      "native_id": "MED:42858405",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42858405"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2708|Dermatology and Skin Diseases",
      "subfield": "general"
    }
  ],
  "title": "Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.",
  "title_text": "Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:18Z",
  "url": "https://research.draconitic.com/paper/5bxp0avn7eyfa",
  "venue": "Dermatology practical & conceptual",
  "versions": []
}